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Biolex, Inc.: Pharmaceutical Production in Plants
For decades, agbiotech companies s
have used the science of genetic s
wengineering and plant-transforma-
tion technologies to make more e
pproductive, efficient, or desirable
plant products. And since 1998,
Pittsboro, North Carolina-based
Biolex, Inc. has been taking this “technology into a new arena: plant-
abased production of hard-to-make
proteins, such as peptides, cyto- g
kines, plasma proteins, monoclonal mantibodies, and other therapeutic
hproteins for human health.
“Our mission is to develop human b
recombinant therapeutic proteins sand monoclonal antibodies that un-
Stil now have been impossible or
expensive to develop in existing o
protein-expression systems,” says pDavid G. Spencer, Ph.D., chief oper-
lating officer and senior vice-presi-
dent of R&D at Biolex. He explains b
that in the more traditional biotech tbusiness, protein-expression sys-
etems involve suspensions in cell
culture—commonly yeast or bacte- l
ria such as E. coli, or mammalian
cells such as Chinese hamster
ovary (CHO) cells. “Coming from
this tradition, we have been looking L
for alternative protein-expression w
systems that can greatly simplify h
the process,” he says. Another tradi- d
tional way was to use transgenic I
animals that were genetically engi- s
neered to secrete a particular thera- t
peutic protein into their milk. “We r
have done something similar, ex- c
cept we have used a plant, duck- t
weed, that can be genetically engi- r
neered to produce high levels of a r
therapeutic human protein,” he says. “
g
c
Roots in Forestry Science d
tThe science behind Biolex got its
start through the work of Dr. Anne-
Marie Stomp at North Carolina a
mState University, Department of For-
estry. “She was trying to take the t
sidea of transforming duckweed, a
common aquatic weed, and explore s
phow widely it can be used in indus-
try,” says Spencer. After securing p
bventure backing for the company,he formed Biolex to take her re- p
cearch into day-to-day practice
ith the idea of producing industrial m
nzymes, vaccines, or therapeutic
roteins. IL
q
1Though there has been
w
lot of talk about trans- a
tenic animals and plants,
tost of those platforms
c
ave not gone forward s
secause of timing and
ppeed,” says David G.
1
pencer, chief operating e
Bfficer and senior vice-
aresident of R&D at Bio-
o
ex. “Ours is the only sta- t
mle transgenic system
that establishes a high-
s
xpressing master plant s
vine in six months.”
u
pDuckweed, the common name for
emna, is a small, aquatic weed t
ith high protein content and a S
ighly clonal nature that allows it to t
ouble in size every 24 to 48 hours. w
ts rapid growth makes it highly de- s
irable for large-scale production in a
he contained and controlled envi- g
onments required for pharmaceuti- g
al proteins. “Duckweed has a for- m
uitous combination of a number of n
eally desirable traits, particularly its t
apid clonal growth,” says Spencer. s
And, it is easily transformed. We a
tet extremely high expression. This
ombination of features makes p
uckweed ideal for our mission of w
lransforming biotherapeutics.”
Plant cells have an area called the g
poplast between the cell wall and
embrane. “It is into this space that g
the duckweed can be induced to
ecrete the processed protein,” o
pays Spencer, explaining that it is
ossible to control the amount of i
srotein that diffuses from the apo-
last into the media surrounding the ilant. To recover the protein, one
an either process the media or ho-
ogenize the plant tissue.
mproved Tissue Yields
iterature on transgenic plants fre-
uently cites results of less than
% tissue-soluble protein. “In other
ords, if you homogenize the tissue
nd recover all of the soluble pro-
ein, less than 1% of that would be
he desired protein,” explains Spen-
er. “In this optimized duckweed
ystem, we have been able to con-
istently achieve 7% tissue-soluble
rotein. That is equivalent to about
0 g/kg dry weight of plant.” When
xpressing a monoclonal antibody,
iolex is able to produce batches of
t least 40 g of the antibody in one
f its bioprocessing suites every
wo to four weeks. “So a lot of
aterial can be produced in a short
ime,“ he says. “And we have de-
igned different production formats,
ome of which are suitable for lower
olumes, others for very high vol-
me, depending on the desired ap-
lication.”
A number of factors control pro-
ein expression level in plants.
ome of them are the features of
he so-called genetic cassette into
hich the gene is placed. The cas-
ette includes components such as
highly active promoter to drive the
ene into high expression. “The
ene also needs to be codon opti-
ized for the plant, meaning you
eed to have a DNA sequence for
he plant’s processing equipment,”
ays Spencer. “So you need to have
promoter, a leader sequence, a
erminator sequence, and signal
eptides, all of which have to work
ell in concert to generate high
evels of expression of the target
ene.”
Understanding this interplay of
enetic components, Biolex sought
o improve expression levels early
n in its founding. “We started a
rocess of systematically develop-
ng a high-expression genetic cas-
ette to produce the proteins we are
nterested in,” says Spencer. “What
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142we did were systematic studies try- a
ing a wide variety of these different v
oconstructs with the same target
protein—just plugging different ones m
lin and out until we got a very high
expression cassette. We did this t





sThe result is the LEX System, Bio-
alex’s program of creating a thera-
opeutic protein from amino acid se-
pquence through scale-up of purified
FcGMP product suitable for clinical
atrials and commercialization. The
icompany started by manufacturing
talpha interferon and human growth
qhormone and then progressed to
pmonoclonal antibodies, plasmino-
agen, and other hard-to-make pro-
rteins. Alpha interferon is currently
cmade in microbial systems, al-
Rthough Spencer points out that
hthese systems are poorly suited for
pthe job. “One would like to be able
to produce it at high expression
tlevels in mammalian cells, but it is a
tcytokine to which most mammalian
bcells are sensitive. They have their
town receptors for it. As a result, it
wis very difficult to get high expres-
asion.” Plants are not sensitive to the
scytokine signals of alpha interferon,
cso it is easy to make them express
sit at high levels.
sThe opposite type of problem is
amonoclonal antibodies where mam-
dmalian cells can express them ex-
ptremely well and at very high levels.
aThe difficulty comes in the product
wrequirements. “If you know that you
Dare going to have to make hundreds
of kilograms of protein to satisfy
cmarket demand, then the expense
Pof a mammalian-cell culture sys-
ptem—setting that up in terms of ca-
ipital costs—becomes prohibitive,”
rexplains Spencer.
eBiolex is pursuing interferon al-
fpha-2b as its lead product. “We have
omade a product that is even more
tpure than what is currently in the
omarket,” says Spencer. “Through-
pout the development of our product,
twe have done head-to-head com-
tparison studies with Intron A, the
pmarketed product, in monkeys, and
bour phase I clinical trial is also de-
signed that way.” Spencer reports
that the Biolex product, BLX-883, S
Thas the same specific anti-viral and
anti-cancer activity as Intron A inssay studies and that all of the in
ivo data look comparable in terms
f antigenicity, potency, and phar-
acokinetics. “Our contaminant
evels are extremely low, lower than
hose reported for the marketed
roduct manufactured via E. coli
ost cell,” he adds. The single main
urdle now is to demonstrate in the
linic that the plant-manufactured
roduct presents no unanticipated
afety issues and that it is not more
ntigenic than proteins from any
ther expression system. The com-
any submitted its first IND to the
DA in December 2004 for BLX-883
nd will be initiating a phase I trial
mmediately. “We will have some of
he clinical results later in the first
uarter and should have a full re-
ort by mid-year,” says Spencer. In
ddition, the compound has already
eceived approval from the Medi-
ines and Healthcare Products
egulatory Agency (MHRA) (the UK
ealth authority) to proceed into
hase I testing.
Biolex is also partnering with no-
able players, such as Centocor, in
he protein and monoclonal-anti-
ody fields. Spencer explains that
he company assists its partners
ith the expression of proteins that
re either hard to express in other
ystems or expensive to express in
urrent systems at the required
cale. Biolex has initiated two GLP
cale-ups with Centocor proteins,
nd four others are pending. In ad-
ition to the monoclonal-antibody
rograms with Centocor, Biolex
lso has executed collaborations
ith Bayer HealthCare, LLC, and
ebiopharm S.A.
In May 2004, Biolex acquired Epi-
yte Pharmaceutical, and with it its
lantibodies technology, the com-
any’s intellectual-property-produc-
ng antibodies in plants. Patent
ights of the technology cover the
xpression of antibodies and their
ragments in plants and protect use
f all species of transgenic plants
hat produce an antibody and meth-
ds of making the transgenic
lants. Spencer says that acquisi-
ion of the Plantibodies patent es-
ate gives Biolex control over plant
roduction of monoclonal anti-
odies.
peedy and Self-Contained
he space of transgenic or alterna-tive expression systems has be-come crowded in the last five to ten
years. “Though there has been a lot
of talk about transgenic animals
and plants, most of those platforms
have not gone forward because of
timing and speed,” says Spencer.
For many transgenic plants—as well
as transgenic animals—you have to
have several generations before
you have a commercial-production
seed bank or flock. “Ours is the only
stable transgenic system that es-
tablishes a high-expressing master
plant line in six months, which
speeds the time to make sufficient
product for scale-up and animal
and human trials,” he says.
The LEX System is contained in
facilities designed to ensure safety
and lot-to-lot reproducibility. “We
are not out in a field, where there is
a public perception that spreading
of transgenic pollen may contami-
nate food crops with drugs,” says
Spencer. Each bioprocessing suite
is fully enclosed, contained to ap-
proximately 200 square feet. And
the plant-based manufacturing sys-
tem largely avoids the risk of con-
tamination by human pathogens, a
limiting factor of human protein pro-
duction in mammalian cells and
transgenic animals.
Biolex has a strong intellectual-
property position around the trans-
formation of duckweed and the
manufacturing of therapeutic pro-
teins in all plants of the family Lem-
naceae. “We are the only company
that controls transformation of the
host and all its subspecies to pro-
duce therapeutic proteins,” says
Spencer. “By comparison, nobody
controls transgenic sheep or corn.”
Chemistry & Biology invites your
comments on this topic. Please
write to the editors at chembiol@
cellpress.com
Alice A. McCarthy is a freelance sci-
ence writer based in Gloucester,
MA (alice@alicemccarthy.com).
